U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07027488) titled 'AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors' on May 19.
Brief Summary: This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) in participants with recurrent locally advanced or metastatic melanoma and other immune-responsive solid tumors. Immune-responsive solid tumors are defined as those for which immune checkpoint inhibitors form part of the standard-of-care therapy.
Study Start Date: Aug., 2025...